- Report
- October 2024
- 192 Pages
Global
From €3222EUR$3,545USD£2,759GBP
€3580EUR$3,939USD£3,066GBP
- Report
- October 2024
- 192 Pages
Global
From €3222EUR$3,545USD£2,759GBP
€3580EUR$3,939USD£3,066GBP
- Report
- April 2025
- 93 Pages
Global
From €5317EUR$5,850USD£4,553GBP
- Report
- March 2025
- 175 Pages
Global
From €4081EUR$4,490USD£3,495GBP
- Report
- August 2024
- 141 Pages
Global
From €2726EUR$2,999USD£2,334GBP
- Report
- August 2022
- 120 Pages
Global
From €4090EUR$4,500USD£3,502GBP
- Report
- April 2025
- 50 Pages
Global
From €2409EUR$2,650USD£2,062GBP
- Report
- April 2025
- 50 Pages
Global
From €2409EUR$2,650USD£2,062GBP
- Report
- April 2025
- 50 Pages
Global
From €2409EUR$2,650USD£2,062GBP
- Report
- April 2025
- 50 Pages
Global
From €2409EUR$2,650USD£2,062GBP
- Report
- November 2022
- 210 Pages
Global
From €2271EUR$2,499USD£1,945GBP
€3245EUR$3,570USD£2,778GBP
Methylxanthines are a class of drugs used to treat respiratory diseases, such as asthma and chronic obstructive pulmonary disease (COPD). They act as bronchodilators, meaning they relax the muscles in the airways, allowing more air to flow through. Methylxanthines are also used to treat other conditions, such as sleep apnea and obesity. They are available in both prescription and over-the-counter forms.
Methylxanthines are generally considered safe and effective, but they can cause side effects such as nausea, headache, and insomnia. They can also interact with other medications, so it is important to talk to a doctor before taking them.
The methylxanthine market is a competitive one, with many companies offering products. Some of the major players in the market include GlaxoSmithKline, Merck, Pfizer, and AstraZeneca. Other companies include Boehringer Ingelheim, Sanofi, and Novartis. Show Less Read more